A Single-centre Open-label Parallel Two-arms Pilot Randomized Clinical Trial of a Booster Recombinant Zoster Vaccine in Solid-Organ Transplant Recipients

Shingles is caused by the same virus that causes chickenpox. After someone has chickenpox, the virus stays in the body and can become active again later in life. This is called shingles.
People who have received a solid organ transplant (such as a kidney, liver, or heart transplant) are 3 to 10 times more likely to get shingles than the general population. In transplant patients, shingles is often more severe. It can spread to other parts of the body and may cause long-lasting nerve pain. These problems can lower quality of life, increase doctor visits and hospital care, and may even affect how well the transplanted organ works.
The shingles vaccine called Shingrix® (recombinant zoster vaccine, RZV) works well in healthy adults and is generally safe for transplant patients. However, about 30% of transplant recipients still develop shingles even after receiving the recommended two doses. This may be because their immune system is weakened by the long-term medicines they take to prevent organ rejection.
The purpose of this clinical trial is to find out whether giving an extra (booster) dose of the shingles vaccine after transplant can improve the immune response in solid organ transplant recipients.
This study aims to answer the following questions:
* How many participants have at least twice as many shingles antibodies (anti-gE antibodies) four weeks after receiving the booster compared to before the booster?
* How strong and how long does the immune response last at 6 and 12 months?
* Is the booster dose safe for transplant patients? In this study, researchers will compare two groups: One group will receive a booster dose of the shingles vaccine. The other group will not receive the booster. They will compare the groups to see differences in immune response, cases of shingles despite vaccination, and any side effects.
Participants in the study will:
* Be randomly assigned (by chance) in a 2:1 ratio to either receive the booster or not.
* Have blood samples taken at the first visit, and again at 1 month, 6 months, and 12 months to measure antibody levels and immune responses.
* Be monitored for any possible side effects.
* Have their medical records reviewed for health events such as side effects or organ rejection.

Start Date01 Apr 2026

Sponsor / Collaborator

Centre Hospitalier Universitaire Vaudois

CTIS2025-524598-17-00

/ Not yet recruitingPhase 4

A randomized, placebo controlled, observer-blind, phase IV pragmatic trial to evaluate the effect of Recombinant Zoster Vaccine (Shingrix®) on incident dementia diagnosis in an older adult population aged ≥76 years in Finland

Start Date31 Mar 2026

Sponsor / Collaborator

GlaxoSmithKline Biologicals (Shanghai) Ltd.

CTIS2025-524944-37-00

/ Not yet recruitingPhase 4

A Pragmatic Randomized Trial to Evaluate the Effect of Recombinant Herpes Zoster Vaccine on Major Adverse Cardiovascular Events and Dementia in Adults Aged 65 Years or Above

Start Date01 Mar 2026

Sponsor / Collaborator

Gentofte Hospital

[+1]

100 Clinical Results associated with Zoster vaccine recombinant, adjuvanted (GlaxoSmithKline)

100 Translational Medicine associated with Zoster vaccine recombinant, adjuvanted (GlaxoSmithKline)

100 Patents (Medical) associated with Zoster vaccine recombinant, adjuvanted (GlaxoSmithKline)

3,428

Literatures (Medical) associated with Zoster vaccine recombinant, adjuvanted (GlaxoSmithKline)

31 Dec 2026·Human Vaccines & Immunotherapeutics

TLR9 and STING agonists adjuvanted varicella-zoster virus glycoprotein E induced a potent and durable nasal vaccine response

Article

Author: Su, Yu-Wen ; Su, Yu-Siang ; Tien, Chih-Feng ; Yu, Guann-Yi ; Tseng, Jen-Chih ; Chuang, Tsung-Hsien ; Chen, Linyi ; Imana, Zaida Nur ; Yang, Jing-Xing ; Liu, Yi-Ling ; Lin, Po-Yen ; Tsai, Wan-Ting ; Huang, Ming-Hsi ; Chen, Jen-Kun

Herpes zoster is caused by the reactivation of latent varicella-zoster virus (VZV), primarily affecting middle-aged and older individuals and often accompanied by severe pain and other complications. Vaccination is an effective preventive measure against this disease. In the present study, we evaluated the adjuvant activity of Toll-like receptor (TLR)9 and TLR7 agonists in combination with stimulator of interferon genes (STING) agonists for a VZV-glycoprotein E (gE)-based vaccine. Among the tested combinations, the CpG-2722 (TLR9 agonist) and 2'3'-c-di-AM(PS)2 (STING agonist) pairing exhibited potent immunostimulatory activity in immune cells and superior adjuvant activity for VZV-gE vaccines in a mouse models. Shingrix, a licensed herpes zoster vaccine, is administered intramuscularly. The CpG-2722/2'3'-c-di-AM(PS)2 combination adjuvanted VZV vaccine, administered intramuscularly, effectively induced higher gE-specific IgG responses than that induced by the Shingrix and imiquimod/2'3'-c-di-AM(PS)2 adjuvant vaccine. Notably, intranasal administration of the CpG-2722/2'3'-c-di-AM(PS)2 adjuvanted VZV vaccine to mice elicited a robust antigen-specific IgA response, which was barely detectable in intramuscularly administered vaccines. Two doses of the intranasal immunization, administered at a two-week interval, provided long-lasting protection, as antigen-specific IgG levels remained elevated for months without booster immunization. Further investigation into the functional mechanism revealed that CpG-2722 combined with 2'3'-c-di-AM(PS)2 induced a strong antigen-dependent T helper 1 (Th1) cytokine response, consistent with the antigen-independent cytokine-inducing properties of this adjuvant combination. This study demonstrates that the TLR9 and STING agonists formulated adjuvant induces a potent and long-lasting immune response, highlighting its potential as a promising adjuvant candidate for nasal VZV vaccines.

01 Apr 2026·JOURNAL OF INFECTION AND CHEMOTHERAPY

Barriers to pediatric COVID-19 vaccination in Japan: A parent survey on convenience and access

Article

Author: Kawabe, Shinji ; Sugiura, Shiro ; Ito, Kenta ; Ogawa, Eiki

BACKGROUND:

In Japan's 2024 pediatric COVID-19 vaccination program, only multi-dose vials were supplied for children aged 6 months to 4 years, limiting smaller clinics' willingness to offer vaccination and potentially restricting access. Evidence on logistical barriers faced by parents in such settings is limited.

METHODS:

We retrospectively reviewed children aged 6 months to 11 years who received COVID-19 vaccination at the Aichi Children's Health and Medical Center between December 2024 and June 2025. Demographic data were extracted from electronic records. Parents completed an anonymous online questionnaire regarding information sources, appointment-seeking behaviors, perceived difficulties, and future vaccination intentions. Residential distance was compared with that of emergency department patients using the Mann-Whitney U test.

RESULTS:

Eighty-three doses were administered to 49 children; 37 were aged 6 months-4 years. Vaccine recipients lived significantly farther from the center than emergency patients (median 17.0 km vs 5.9 km, p < 0.001). The questionnaire response rate was 69% (34/49). Social media was the main information source (65%), whereas only 9% received information from healthcare providers or public health centers. Most parents (88%) were "very troubled" by limited vaccination sites, and 41% contacted 10 or more facilities when seeking an appointment. The median travel time was 60 min.

CONCLUSIONS:

Regarding COVID-19 vaccinations, it has been found that access to vaccination facilities and vaccine cost can be barriers, and that information on social media is important for parents. We believe that focusing on measures to address these issues can lead to improved vaccination rates.

01 Apr 2026·VACCINE

The role of health beliefs in COVID-19 vaccination acceptance: A Meta-analysis

Review

Author: Vafeiadis, Michail ; Li, Ruobing ; Shen, Fuyuan ; Hou, Zhihui

This study employed a meta-analytic approach to examine the relationships between the Health Belief Model (HBM) constructs and COVID-19 vaccination acceptance. A comprehensive literature search identified 77 eligible studies with a combined sample size of 83,995 participants. Quantitative synthesis of the extracted data revealed that perceived benefits (r = 0.40) was the strongest positive predictor of individuals' vaccine acceptance, indicating a medium-to-large effect. Perceived severity (r = 0.17) and susceptibility (r = 0.18) to COVID-19 were also significant positive predictors, each with small-to-medium effect sizes. Cues to action (r = 0.11) and self-efficacy (r = 0.10) were also positively associated with vaccine acceptance, although the effects were small. In contrast, perceived barriers to vaccination (r = -0.25) were negatively associated with vaccine acceptance, approaching a medium effect in size. Several of these associations were moderated by study characteristics, including how the variables were operationalized (intention, hesitancy, refusal, etc.), the vulnerability of the study sample, the respondent type (parents vaccinating children vs. adults vaccinating themselves), the vaccine development stage, and the variant phase. Overall, these findings contribute to a deeper understanding of the psychological mechanisms underlying vaccine acceptance and hesitancy, and offer practical implications for developing targeted communication strategies to promote COVID-19 and other vaccinations.

193

News (Medical) associated with Zoster vaccine recombinant, adjuvanted (GlaxoSmithKline)

05 Feb 2026

·www.biopharmadive.com

Earnings roundup: AbbVie angst, a bifurcated vaccine market and Bristol Myers’ waiting game

With quarterly earnings underway, BioPharma Dive is providing a snapshot of some companies results and how theyre being received by investors. Today, were offering insight into the latest numbers from Bristol Myers Squibb, GSK and AbbVie.AbbVie angstAbbVie reported $16.6 billion worth of net revenue in the final three months of 2025, a 10% year-over-year increase. The total was a bit above what analysts generally predicted, with the vast majority of revenue upside coming from a surprise performance by Humira, according to David Risinger of Leerink Partners.Once the worlds best-selling drug, Humira has been in decline since generic competition entered the market a few years ago. But in the fourth quarter, the $1.2 billion the drug brought in was almost 30% higher than Wall Street expectations.Most of AbbVies other products were roughly in-line with estimates, with one exception being Rinvoq, which fell below with a quarterly revenue of nearly $2.4 billion. Those performances may be why company shares were, at one point Wednesday, down more than 6%.Phipps, of William Blair, highlighted how it was the second quarter in a row that Rinvoq didnt meet analyst forecasts. At the same time, Skyrizi the other immune system-regulating drug AbbVie has pegged as a partial successor to Humira had only a slight beat.Investors continue to have concerns about growing competition for the companys [immunology] franchises, Phipps wrote in a note to clients. One particular point of worry, he added, is how Rinvoq and Skyrizi will fare in the inflammatory bowel disease market since the relatively recent entries of Johnson & Johnsons Tremfya and copycat versions of Stelara.AbbVie recorded $61.2 billion in net revenue across all of 2025, reflecting an 8.6% annual gain. For this year, the company said adjusted diluted earnings per share will land somewhere between $14.37 to $14.57.Though such a range should be viewed positively by investors, Cantor Fitzgeralds Carter Gould argues that the focus is more on the revenue and product-level guides, especially for Skyrizi. Jacob BellA bifurcated vaccine marketVaccine makers are facing a unique challenge in one of their largest markets. The sudden, drastic shift in U.S. vaccine policy, combined with growing skepticism and declining immunization rates, has imperiled sales as well as future vaccine research.Moderna CEO Stephane Bancel has already reportedly said his company wont invest in late-stage vaccine trials due to the contentious climate. Now, some of the worlds top vaccine manufacturers are reporting slowing sales numbers that could provide insight into how the situation will play out in the coming years.Last week, French pharmaceutical Sanofi said that vaccine sales fell 2.5% in the fourth quarter and are anticipating negative sales growth next year. Thats in large part due to performance in the U.S., where revenue dipped for immunizations against polio, meningitis, influenza and respiratory syncytial virus.GSK is now reporting similar trends.The British drugmaker said Wednesday that while overall vaccine sales were up 2% in the fourth quarter, its growth was driven by sales in Europe and elsewhere, while U.S. numbers tumbled for its influenza, RSV and shingles vaccines. Its shingles vaccine, Shingrix, faced the sharpest decline, with sales plummeting 17% in the U.S. due to heightening difficulty reaching unvaccinated individuals.While the earnings for adult shots were the most affected, GSK has yet to see how the new changes to the U.S. childhood immunization schedule will affect the rest of GSKs vaccines. Nina Mojas, head of the companys global product strategy, said the impact should be manageable given its broad vaccine portfolio.“We continue to monitor the evolving pediatric vaccine landscape in the U.S, Mojas said during an earnings call.Last month, the Centers for Disease Control and Prevention rolled back six immunization recommendations for children in response to a directive from President Trump. The schedule was scaled down to recommend 11 vaccines from the previous 17.At least so far, however, insurance coverage remains as before, Mojas added. GSK expects vaccine sales to either be stable or decline by a low-single digits percent in 2026. Delilah AlvaradoBristol Myers waiting gameBristol Myers growth portfolio lived up to its name in 2025, helping the company deliver fourth-quarter and full-year revenues that were a tick higher than analyst estimates.The portfolio spans 18 products, most of which are used to treat cancer or regulate the immune system. Collectively, revenue from this group rose 17% last year, and accounted for 55% of the total $48.2 billion Bristol Myers recorded. Standout performances, according to William Blair analyst Matt Phipps, came from the anemia shot Reblozyl, the heart drug Camzyos and the cell therapy Breyanzi.Wall Street had hoped to see Cobenfy, a first-of-its-kind treatment for schizophrenia that generated $51 million in the fourth quarter, bring in a bit more during that three-month period. Bristol Myers took control of Cobenfy back in 2024, through an acquisition worth $14 billion. The company has been looking to ramp up sales by notching additional approvals in more common conditions like bipolar disorder or the agitation, psychosis and cognition problems that often accompany Alzheimers disease.A trio of late-stage studies evaluating Cobenfy against Alzheimers psychosis are set to produce results this year. Analysts have pinpointed those trials as some of Bristol Myers most important near-term catalysts, along with Phase 3 readouts for the companys experimental myeloma drugs iberdomide and mezigdomide and its blood thinner milvexian.We see the continued outperformance of the growth portfolio as a positive signal on execution, with attention pointing to [back half of the year] datasets for further confidence on the mid- to long-term revenue trajectory, wrote Raymond James analyst Sean McCutcheon in a note to clients.Bristol Myers is under pressure to further build out that portfolio, given the steep declines across most of its legacy drugs like Revlimid and Pomalyst. Its top-seller, Eliquis, is also poised to lose key patent protections in 2028, putting more than a quarter of Bristol Myers annual revenue in jeopardy.For 2026, the company forecasts revenue reaching around $46 billion to $47.5 billion and non-GAAP earnings per share in the range of $6.05 to $6.35. Those figures are in line to moderately above Wall Street expectations, McCutcheon wrote.Shares of Bristol Myers climbed more than 3% Thursday. Jacob Bell '

AcquisitionVaccinePhase 3Clinical ResultCell Therapy

04 Feb 2026

·www.fiercepharma.com

As CEO, Luke Miels wants GSK to be more 'product-centric'

Luke Miels inherited the GSK CEO role as the company posted what he called strong performance last year. In his first investor update as GSK’s CEO, Luke Miels defined a core of his vision for the company’s next chapter: “We need to be more product-centric as a company.”Being product-centric means everyone at GSK, from R&D and manufacturing to commercialization and administrative functions, should be clear about how their role drives the company’s goal of making drugs that improve clinical outcomes for patients, Miels said during a press call Wednesday.“When you look at the level of communication, discussions, focus time that a company spends, I want to really see that to be massively dominated by products,” he said.In addition to product-centricity, Miels also wants GSK to have more “scientific courage” to accelerate its pipeline and be “more agile to capitalize on opportunities.” Miels succeeded Emma Walmsley to become GSK’s new CEO at the beginning of 2026, inheriting the role as GSK posted what he called strong performance last year. Full-year revenue grew 7% at constant exchange rates to 32.7 billion pounds sterling ($44.9 billion), and a fourth-quarter haul of 8.6 billion pounds came 2% ahead of analysts’ consensus.Even though GSK expects milder sales growth—between 3% and 5%—this year, Miels stood by the company’s ambitious target of generating more than 40 billion pounds by 2031, which was set when he was chief commercial officer. GSK will test its new CEO’s product-centric approach this year with two key launches: long-acting respiratory disease biologic Exdensur and multiple myeloma antibody-drug conjugate Blenrep, both approved by the FDA in the fourth quarter of 2025.With Exdensur, GSK has transferred its Nucala sales force to detail the new half-yearly regimen, leaving Nucala’s chronic obstructive pulmonary disease (COPD) launch to the Trelegy team, Miels said on an investor call Wednesday.“We need to place our bets on the future, and the ultimate future with IL-5 and higher [eosinophils] is gonna be long-acting Exdensur for COPD,” he said.Exdensur’s current FDA approval covers its use as an add-on therapy for severe eosinophilic asthma. In COPD, GSK has two phase 3 trials, Endura-1 and -2, for testing the anti-IL-5 antibody as an add-on therapy to treat moderate to severe COPD with type 2 inflammation. In the fourth quarter, GSK launched a third phase 3 trial, dubbed Vigilant, to assess early use of Exdensur in COPD patients who have had one exacerbation and are at a high risk for future exacerbations.Despite the many biologics available for respiratory diseases, GSK still sees “a significant opportunity in the bio-naïve population, as only 27% of U.S. eligible patients are on a biologic, and market research shows that 97% of patients would prefer or like to switch to a biologic with six-monthly dosing,” Nina Mojas, GSK’s president of global product strategy, said on the investor call.As for Blenrep, the BCMA agent remains a show-me story after making a comeback from a previous market withdrawal. Despite lofty peak sales figures, Mojas acknowledged that the product’s launch will be a slow ramp as GSK supports prescribers and patients to ensure a positive first experience.Despite its being an off-the-shelf option compared with BCMA CAR-T therapies, Blenrep comes with notable eye toxicity and is therefore only available through an FDA-mandated REMS safety program. To mitigate that side effect, GSK has educated about 18,000 eye care professionals in the U.S., enabling their collaboration with oncologists, Mojas said. GSK launched Blenrep in the U.K. before securing an FDA go-ahead in late October, and the company expects to see similar interest in the drug albeit slow uptake because of the need for coordination with eye care professionals.Still, Miels highlighted a roughly 50-50 split between academic and community practices during early adoption of Blenrep.“Our strategy is to focus on the community,” he said. “With a product that is being relaunched and not a lot of experience in the community, I think this is an encouraging trajectory.” Meanwhile, the vaccines business at GSK is undergoing significant uncertainty due to disruptive U.S. policy changes.In the fourth quarter, GSK’s sales from vaccines grew 4% year over year to 2.3 billion pounds, bringing the full-year total to nearly 9.2 billion pounds ($12.6 billion).The company’s flagship shingles vaccine Shingrix delivered a 20% sales increase during the fourth quarter thanks to Europe and international markets, while the U.S. logged a 17% decrease as the remaining unvaccinated market proves difficult to penetrate.The U.S. Department of Health and Human Services, under the leadership of Secretary Robert F. Kennedy Jr., has challenged many longtime vaccine practices, including recently walking back recommendations for six immunizations for children. The moves have dealt a number on overall vaccines sales at several companies, although GSK expects the impact to be “manageable.”“We continue to monitor the evolving pediatric vaccine landscape in the U.S.,” Mojas said. “At this time, insurance coverage remains as before, and we expect the recent HHS changes to be manageable.”For 2026, GSK expects sales from vaccines to decline in the low-single-digit percentage or remain stable.

Phase 3Executive ChangeVaccineDrug Approval

29 Dec 2025

·www.fiercepharma.com

Acquisitive Sanofi keeps deals coming, laying out $2.2B for hepatitis vaccine maker Dynavax

Its acquisition also grants Sanofi access to Dynavax Technologies’ promising shingles prophylactic Z-1018, which is currently in phase 1/2 testing and could eventually challenge GSK’s incumbent shot Shingrix, if approved. Following a feud with activist investor Deep Track Capital in the first half of 2025, vaccine developer Dynavax Technologies has rounded out the year by agreeing to sell itself to France’s Sanofi.To get its hands on the Emeryville, California-based company and its approved adult hepatitis B vaccine Heplisav-B, Sanofi will pay $15.50 per Dynavax share in cash, which works out to a total deal value of roughly $2.2 billion, the French pharma said in a Dec. 24 press release.The acquisition, which is expected to close in 2026’s first quarter, also grants Sanofi access to Dynavax’s promising shingles prophylactic Z-1018, which is currently in phase 1/2 testing and could eventually challenge GSK’s incumbent shot Shingrix, if approved.The addition of Dynavax’s hepatitis vaccine Heplisav-B is expected to help round out Sanofi’s armamentarium of approved adult immunizations, which has traditionally leaned heavily on the drugmaker’s roster of influenza shots. In 2025’s third quarter, Sanofi reported that its overall vaccine sales had slipped nearly 8% to 3.4 billion euros, which the company blamed in October on “lower influenza sales.”Meanwhile, Sanofi already boasts a combination hepatitis B vaccine for young children in Vaxelis, which also protects against conditions like tetanus, pertussis and diphtheria.Given that Heplisav-B is indicated for adults, Dynavax’s commercial vaccine won’t be affected by the recent vote from the Centers for Disease Control and Prevention’s Advisory Committee on Immunization Practices to remove a recommendation for universal hepatitis B vaccination for infants at birth in the U.S.The buyout comes amid broader shifts in vaccination trends and policy in the U.S., especially for children, under a Department of Health and Human Services led by noted vaccine skeptic Robert F. Kennedy Jr. Dynavax’s adult hepatitis vaccine Heplisav-B, approved by the FDA in 2017, sets itself apart from other shots in the indication thanks to its two-dose regimen administered over just one month, Sanofi noted in its release. By comparison, other hepatitis B vaccines must be given in three doses over six months.For all of 2024, Dynavax recorded Heplisav-B sales of $268 million, which represented a 26% jump over the sum the vaccine generated the year before.Meanwhile, the company’s experimental shingles vaccine Z-1018 displayed promising signals over the summer in the first part of a phase 1/2 study, which looked at various formulations and dosing regimens of the recombinant subunit shot in healthy adults between the ages of 50 and 69 years.In the trial, which measured Z-1018 against GSK’s Shingrix, the formulation Dynavax has decided to go forward with in the second part of the study helped trigger a 100% humoral vaccine response rate—a measure of antibody production—at one month following a second dose, compared to 96.9% in the study’s Shingrix cohort.In terms of responses for gE-specific CD4+ T cells, the study’s Z-1018 group showed a cellular immune response rate of 89.7% versus 93.5% for the Shingrix arm, Dynavax said in August.“Joining Sanofi will provide the global scale and expertise needed to maximize the impact of our vaccine portfolio,” Ryan Spencer, Dynavax’s chief executive, said in a statement.“We believe Sanofi’s commercial reach, development capabilities, and commitment to evidence-based immunization will amplify the opportunity for Heplisav-B and our innovative pipeline to address important public health needs, further advancing our mission to help protect the world against infectious disease,” he continued.Dynavax has accepted Sanofi’s offer in the wake of a contentious battle with activist investor Deep Track earlier in 2025.Back in February, Deep Track intensified demands for Dynavax to refocus its efforts on its lone approved product, Heplisav, and forego what the investor called a “misguided empire-building exercise” of pursuing external asset acquisitions. At the time, Deep Track estimated that the nearly eight-year-old vaccine Heplisav could generate more than $1 billion through 2030. A key part of Deep Track’s plan was to instill four of its own picks to Dynavax’s board.But Dynavax held its ground and ultimately prevailed at its annual meeting in June, reelecting all four of its own candidates and defeating Deep Track’s attempts to unseat the directors, Reuters reported over the summer. Sanofi’s decision to snap up Dynavax follows a number of other high-profile acquisitions by the French Big Pharma in 2025.In a massive deal worth up to $9.5 billion, Sanofi in June agreed to purchase Blueprint Medicines, gaining access to the company’s portfolio of rare immunological disease treatments, including the systemic mastocytosis pill Ayvakit. Blueprint in 2024 estimated that Ayvakit could generate $2 billion in peak sales. Meanwhile, Sanofi in July laid out $1.15 billion upfront for Vicebio, securing preclinical and phase 1 vaccine candidates to grow its pipeline for respiratory syncytial virus (RSV) beyond mRNA.Vicebio’s most advanced candidate comes in the form of VXB-241, a bivalent vaccine prospect taking aim at RSV and human metapneumovirus.

VaccineAcquisitionDrug ApprovalClinical Result

100 Deals associated with Zoster vaccine recombinant, adjuvanted (GlaxoSmithKline)

External Link

KEGG	Wiki	ATC	Drug Bank
-	Zoster vaccine recombinant, adjuvanted (GlaxoSmithKline)	J07BK03	-

R&D Status

Approved

10 top approved records.

to view more data

Indication	Country/Location	Organization	Date
Neuralgia, Postherpetic	European Union	GlaxoSmithKline Biologicals SA	21 Mar 2018
Neuralgia, Postherpetic	Iceland	GlaxoSmithKline Biologicals SA	21 Mar 2018
Neuralgia, Postherpetic	Liechtenstein	GlaxoSmithKline Biologicals SA	21 Mar 2018
Neuralgia, Postherpetic	Norway	GlaxoSmithKline Biologicals SA	21 Mar 2018
Herpes Zoster	Canada	GlaxoSmithKline, Inc.	13 Oct 2017

Developing

10 top R&D records.

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Influenza, Human	Phase 3	Germany	GlaxoSmithKline Biologicals (Shanghai) Ltd.	02 Oct 2013
Lung Injury	Phase 2	Italy	GlaxoSmithKline Biologicals (Shanghai) Ltd.	22 Mar 2019
Pulmonary Disease, Chronic Obstructive	Phase 2	Italy	GlaxoSmithKline Biologicals (Shanghai) Ltd.	22 Mar 2019

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


ASH2025	Not Applicable	Paraproteinemias	89	Recombinant adjuvanted zoster vaccine	laqhmqemjt(isgobhcdun) = Adverse events due to vaccination included fever (n=32, 36.0%), pain (n=31, 34.8%) and redness (n=28, 31.5%) at the injection site while 4 (4.5%) patients reported none. itwvxbbfva (lwqzzzrcfl ) View more	Positive	06 Dec 2025
EULAR2025	Not Applicable	Musculoskeletal Diseases	150	Recombinant zoster vaccine (RZV)	roevtpuoav(sdmapwspyx) = By then, pain at the site of injection in 97 (32.7%) patients was the most frequent AE, followed by fever (42 (14.1%)), fatigue (28 (9.4%)), musculoskeletal pain (24 (8.1%)), swelling at the injection side (19 (6.4%)) and redness at the injection side (19 (6.4%)). Infections (14 (4.7%)), worsening of the disease (11 (3.7%) or other AEs (n=23 (7.7%) were reported until M3. mvrumdoavy (utfwnnidre ) View more	Positive	11 Jun 2025
NCT06001606 (EULAR2025)	Phase 3	Systemic Lupus Erythematosus	60	HZ/su vaccine	scbwuufqrz(pgcrtwhyuv) = jvzbqpomvy ryadpdszeq (agovwlkqng, 460.0 - 1775.8)	Positive	11 Jun 2025
NCT02723773 (ZOE-LTFU, Literature \| NEWS) Manual	Phase 3	Herpes Zoster	7,273	Herpes Zoster Vaccine GSK1437173A	vsimciopld(mwfksefawb) = mtqpmyrhgt cszcbiishn (bhznllnxwb, 73.7 - 84.6) View more	Positive	12 May 2025
NCT04091451 (CTgov)	Phase 3	Herpes Zoster	1,430	Herpes Zoster subunit (HZ/su) vaccine (GSK1437173A) (HZ/su Group)	tcfdcwzhzl = wpafouxmwr ehbzkxzarv (zyjfifctvf, odmoraifka - nchuuyuxbn) View more	-	30 Mar 2025
				Placebo (Placebo Group)	tcfdcwzhzl = qrcwhqulli ehbzkxzarv (zyjfifctvf, jideizzlbt - jpttwdiwzf) View more
NCT05219253 (Pubmed \| Vaccine)	Phase 3	Herpes Zoster Adjuvant	-	Adjuvanted Recombinant Zoster Vaccine (RZV)	sunmaplbxm(jjcsywubzz) = vcfroabhgw hhvetbtxwf (ijqhvbcwik, 78.4 - 91.3)	Positive	01 Mar 2025
NCT03591770 (CTgov)	Phase 4	Colitis, Ulcerative	15	SHINGRIX (UC Patients on Tofacitinib Monotherapy)	tqbzckfjqy = mnxvnzquvx htabzgzsvr (ablpdfzjuc, feavwwrfco - lvsaxjsfau) View more	-	21 Feb 2025
				SHINGRIX (UC Patients on Anti-TNF Monotherapy)	tqbzckfjqy = oirekiqjia htabzgzsvr (ablpdfzjuc, cfeudkddpp - ajadxjuwlx) View more
NCT05007041 (Pubmed \| JAMA Netw Open)	Phase 3	Herpes Zoster \| Influenza, Human	267	Adjuvanted Recombinant Zoster Vaccine (RZV) and Adjuvanted Inactivated Influenza Vaccine (aIIV4)	nxacphhtzt(cagknkjkfd) = dmzlncpjfi gyxglcyvjr (ktjefletqh )	Positive	24 Oct 2024
				Adjuvanted Recombinant Zoster Vaccine (RZV) and Quadrivalent High-Dose Inactivated Influenza Vaccine (HD-IIV4)	nxacphhtzt(cagknkjkfd) = wotxabookf gyxglcyvjr (ktjefletqh )
NCT04169009 (CTgov)	Phase 4	Herpes Zoster	105	vOka varicella zoster virus (ZVL)+Zostavax (ZVL) (ZVL >5 Years Previously (Cohort 1))	mpifamjimq(apeitghdum) = yuvjddxrdc emeaoluzxm (vavooqakvz, NA) View more	-	15 Oct 2024
				ZVL (ZVL 6-12 Months Previously (Cohort 3))	mpifamjimq(apeitghdum) = xalybjjfcv emeaoluzxm (vavooqakvz, NA) View more
NCT04869982 (CTgov)	Phase 4	Herpes Zoster	6,138	RZV (RZV Group)	ifxnyowumn = wmiwtasgnm dbjrpkhvzu (gbbugcihyq, ohwliymwcz - melmncoxmd) View more	-	19 Sep 2024
				Placebo (Placebo Group)	ifxnyowumn = ajuoogcgnw dbjrpkhvzu (gbbugcihyq, ymbapsedqq - uwldfggtlc) View more

Translational Medicine

Boost your research with our translational medicine data.

view full example data

Deal

Boost your decision using our deal data.

view full example data

Core Patent

Boost your research with our Core Patent data.

view full example data

Clinical Trial

Identify the latest clinical trials across global registries.

view full example data

Approval

Accelerate your research with the latest regulatory approval information.

view full example data

Regulation

Understand key drug designations in just a few clicks with Synapse.

view full example data

AI Agents Built for Biopharma Breakthroughs

Accelerate discovery. Empower decisions. Transform outcomes.

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Start your data trial now!

Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis